Bharat Biotech
-

Coronavirus: Bharat Biotech gets approval for clinical trials of Covaxin on children aged 2-18
Scroll Staff
-

Coronavirus: No Covaxin shot for 18 to 44 age group in Delhi from Thursday
Scroll Staff
-

As Indian government offers some answers on Covaxin patent rights, more questions emerge
R Ramakumar
-

Coronavirus: 18 states getting direct supply of Covaxin since May 1, says Bharat Biotech
Scroll Staff
-

Covid-19: Covaxin price reduced to Rs 400 per dose from Rs 600 for states
Scroll Staff
-

Whose intellectual property is Bharat Biotech’s publicly funded Covaxin? India deserves an answer
R Ramakumar
-

Coronavirus: Covaxin priced at Rs 1,200 for private companies, Rs 600 for states
Scroll Staff
-
Coronavirus: Covaxin shows 78% efficacy in phase 3 interim analysis, says Bharat Biotech
Scroll Staff
-

Covishield vaccine to cost Rs 400 per dose for states, Rs 600 for private hospitals: Serum Institute
Scroll Staff
-

Coronavirus: Covaxin neutralises double mutant strain, other variants, says ICMR
Scroll Staff
-

India’s decision to liberalise vaccine sales likely to push up prices – and block access to millions
R Ramakumar
-

Coronavirus: Haffkine Biopharma to produce Covaxin after Centre grants approval to Maharashtra
Scroll Staff
-

Coronavirus: 320 doses of Covaxin missing from Jaipur hospital, FIR filed
Scroll Staff
-

Coronavirus: Centre’s expert panel allows clinical trials of third dose of Covaxin
Scroll Staff
-

Coronavirus: Bharat Biotech, AstraZeneca studying vaccine shots for children, says AIIMS chief
Scroll Staff
-

Brazil refuses permission to import Covaxin, Bharat Biotech says it will fulfil requirements
Scroll Staff
-

Coronavirus: SC stays cases before High Courts on petitions seeking priority vaccination for lawyers
Scroll Staff
-

Bharat Biotech’s Covaxin can drop ‘clinical trial mode’ tag, no consent form needed anymore
Scroll Staff
-

Covaxin is safe and immunogenic, but cannot determine efficacy by second phase trials: Lancet study
Scroll Staff
-

Disclose your capacity to manufacture Covid vaccines, Delhi HC tells Serum Institute, Bharat Biotech
Scroll Staff